Bat virome

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

Retrieved on: 
Wednesday, August 4, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, COVID-19

RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.

Key Points: 
  • RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.
  • The SARS-CoV-2 ASR will provide researchers and pathologists with a powerful technology for the detection of SARS-CoV-2 in fixed tissues.
  • During the pandemic, RNAscope probes have been an essential tool in elucidating the pathology of this devastating virus in over one hundred COVID-19 publications to date."
  • Bhatnagar J, Gary J, Reagan-Steiner S, Estetter LB, Tong S, et al.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Zoonoses, Bat virome, Viruses, Health, Hypersensitivity, Type IV hypersensitivity, DTH, Immunology, COVID-19, Severe acute respiratory syndrome, Tonix Pharmaceuticals

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Zoonoses, Bat virome, Viruses, Health, Hypersensitivity, Type IV hypersensitivity, DTH, Immunology, COVID-19, Severe acute respiratory syndrome, Tonix Pharmaceuticals

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

Ondine Biomedical to present SARS-CoV-2 results at the 19th Congress of the European Society of Photobiology

Retrieved on: 
Tuesday, August 3, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Ondine

Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.

Key Points: 
  • Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many pathogens including MRSA, Candida auris and SARS-Cov-2.
  • Dr. Nicolas Loebel, Ondine Biomedicals President and Chief Technology Officer, will present the results in the Photomedicine and SARS-CoV-2/ASP-ESP Symposium.
  • Ondine Biomedical Inc. is a Canadian headquartered, medical device company led by Founder and CEO, Carolyn Cross.

Global Coronavirus (COVID-19) Vaccine Market to 2026 By Infection Type, Vaccine Type, Product Type, Route of Administration, Patient Type, End User, Region - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Health, Pharmaceutical, Coronaviridae, Medicine, Health sciences, Zoonoses, COVID-19 vaccines, Sarbecovirus, Bat virome, Clinical trials, COVID-19 vaccine, Severe acute respiratory syndrome, Coronavirus, COVID-19

The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is driven by the increasing prevalence of this disease across different parts of the globe.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company, and region.

JBS Couros launches antiviral leather

Retrieved on: 
Thursday, July 22, 2021
Sarbecovirus, Animal diseases, Infectious diseases, Medical specialties, Bat virome, Severe acute respiratory syndrome, Antiviral drug

SÃO PAULO, July 22, 2021 /PRNewswire/ -- JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19. At processing stage, a silver microparticle additive is added to the leather coating   providing it with antiviral qualities.

Key Points: 
  • SO PAULO, July 22, 2021 /PRNewswire/ --JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19.
  • At processing stage, a silver microparticle additive is added to the leather coating providing it with antiviral qualities.
  • "Our leather has undergone scientific tests that prove the inactivation of the SARS-Cov-2 virus.
  • "The use of this technology increases the contact surface of silver and its prominence in the leather, enabling antiviral action," says researcher Lucio Freitas, who participated in the tests of the new material.

US COVID-19 Surveillance Needs an Urgent Boost, Says AHF

Retrieved on: 
Tuesday, July 20, 2021
Infectious diseases, Genetics, Public policy, Government, Healthcare reform, White House, Federal Government, Health, State, Local, Public policy, Other Policy Issues, Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Variant, SARS-CoV-2 Delta variant

New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.

Key Points: 
  • New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.
  • The most common strain of the virus is the highly infectious Delta variant, but the US is falling behind other developed countries in tracking and identifying new strains.
  • SARS-CoV-2 is highly prone to genetic variation as it replicates and spreads across different populations.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005833/en/

Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

Retrieved on: 
Wednesday, July 14, 2021
Science, Other Science, Biotechnology, General Health, Health, Medical devices, Infectious diseases, Genetics, Coronaviridae, Sarbecovirus, Zoonoses, Medical tests, Medical genetics, Bat virome, Hologic, Severe acute respiratory syndrome coronavirus, Molecular diagnostics, Severe acute respiratory syndrome, COVID-19

Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.
  • The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the genetic material of the pathogen causing COVID-19.
  • This new CE Mark demonstrates our commitment to providing European consumers and healthcare providers as many options as possible to manage the ongoing pandemic, said Jan Verstreken, Hologics group president, International.
  • Hologic, The Science of Sure, Aptima, and Panther are registered trademarks of Hologic, Inc. in the United States and/or other countries.

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

Retrieved on: 
Tuesday, July 13, 2021
Coronaviridae, Respiratory diseases, Zoonoses, Sarbecovirus, Atypical pneumonias, Bat virome, COVID-19, Occupational safety and health, TLR2, Severe acute respiratory syndrome, COVID-19 vaccine

By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.

Key Points: 
  • By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.
  • The Phase I study is a randomized, double-blind and placebo-controlled, single and multiple ascending dose study.
  • The easy-to-use nasal spray could be helpful in protecting at-risk populations, such as the elderly or patients with chronic respiratory diseases.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

SaNOtize’s Anti-Viral Treatment Made Available in Israeli Pharmacies

Retrieved on: 
Thursday, July 8, 2021
Medical devices, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Coronaviridae, Sarbecovirus, Health, Medicine, Bat virome, Severe acute respiratory syndrome, Virus

Enovid was granted an emergency use authorization as a medical device by Israels Ministry of Health earlier this year.

Key Points: 
  • Enovid was granted an emergency use authorization as a medical device by Israels Ministry of Health earlier this year.
  • Enovid releases a small dose of nitric oxide (NO), a natural nanomolecule with proven anti-microbial properties including against SARS-CoV-2, the virus that causes COVID-19.
  • SaNOtize is also pleased to announce the appointments of Dan Suesskind and Elaine Campbell to its Board of Directors.
  • The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections.